PhaseBio goes public in downsized offering of $46 million
The company, developing a reversal agent for an antiplatelet therapy in-licensed from AstraZeneca, had proposed an IPO at $12-14 per share.
The company, developing a reversal agent for an antiplatelet therapy in-licensed from AstraZeneca, had proposed an IPO at $12-14 per share.
The company plans to use the money for a registrational Phase III study of its severe oral mucositis drug, which showed positive results in Phase IIb trial data presented in June.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.